                         SEQUENCE LISTING

<110>  Juno Therapeutics, Inc.
       SALMON, Ruth Amanda
       CHADWICK, Eric Martin
       HAUSE, Ronald James JR.
       PONCE, Rafael Angel
       LEVITSKY, Hyam I
       JIANG, Yue
 
<120>  MOUSE MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH 
       IMMUNOTHERAPIES

<130>  735042011840

<140> Not Yet Assigned
<141> Concurrently Herewith

<150>  62/527,030
<151>  2017-06-29

<150>  62/563,635
<151>  2017-09-26

<150>  62/584,731
<151>  2017-11-10

<160>  10    

<170>  PatentIn version 3.5

<210>  1
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Mouse N-terminal CD8 alpha signal peptide

<400>  1

Met Ala Ser Pro Leu Thr Arg Phe Leu Ser Leu Asn Leu Leu Leu Leu 
1               5                   10                  15      


Gly Glu Ser Ile Ile Leu Gly Ser Gly Glu Ala 
            20                  25          


<210>  2
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-murine CD19 variable heavy chain derived from the 1D3 rat 
       monoclonal anti- CD19 antibody

<400>  2

Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr Ser Val Lys 
1               5                   10                  15      


Leu Ser Cys Lys Val Ser Gly Asp Thr Ile Thr Phe Tyr Tyr Met His 
            20                  25                  30          


Phe Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Arg Ile 
        35                  40                  45              


Asp Pro Glu Asp Glu Ser Thr Lys Tyr Ser Glu Lys Phe Lys Asn Lys 
    50                  55                  60                  


Ala Thr Leu Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Lys Leu 
65                  70                  75                  80  


Ser Ser Leu Thr Ser Glu Asp Thr Ala Thr Tyr Phe Cys Ile Tyr Gly 
                85                  90                  95      


Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Val Met Val Thr Val Ser 
            100                 105                 110         


<210>  3
<211>  105
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-murine CD19 variable light chain derived from the 1D3 rat 
       monoclonal anti- CD19 antibody

<400>  3

Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Thr Ser Leu Gly Glu 
1               5                   10                  15      


Thr Val Thr Ile Gln Cys Gln Ala Ser Glu Asp Ile Tyr Ser Gly Leu 
            20                  25                  30          


Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Gln Leu Leu Ile Tyr 
        35                  40                  45              


Gly Ala Ser Asp Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Thr Ser Met Gln Thr Glu 
65                  70                  75                  80  


Asp Glu Gly Val Tyr Phe Cys Gln Gln Gly Leu Thr Tyr Pro Arg Thr 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Glu Leu 
            100                 105 


<210>  4
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Murine IgG3 hinge region

<400>  4

Pro Arg Ile Pro Lys Pro Ser Thr Pro Pro Gly Ser Ser Cys Pro Pro 
1               5                   10                  15      


<210>  5
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  murine CD28 transmembrane region

<400>  5

Phe Trp Ala Leu Val Val Val Ala Gly Val Leu Phe Cys Tyr Gly Leu 
1               5                   10                  15      


Leu Val Thr Val Ala Leu Cys Val Ile Trp Thr 
            20                  25          


<210>  6
<211>  48
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  intracellular signaling domain of murine 41BB

<400>  6

Ser Val Leu Lys Trp Ile Arg Lys Lys Phe Pro His Ile Phe Lys Gln 
1               5                   10                  15      


Pro Phe Lys Lys Thr Thr Gly Ala Ala Gln Glu Glu Asp Ala Cys Ser 
            20                  25                  30          


Cys Arg Cys Pro Gln Glu Glu Glu Gly Gly Gly Gly Gly Tyr Glu Leu 
        35                  40                  45              


<210>  7
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Intracellular signaling domain of murine CD3

<400>  7

Arg Ala Lys Phe Ser Arg Ser Ala Glu Thr Ala Ala Asn Leu Gln Asp 
1               5                   10                  15      


Pro Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr 
            20                  25                  30          


Asp Val Leu Glu Lys Lys Arg Ala Arg Asp Pro Glu Met Gly Gly Lys 
        35                  40                  45              


Gln Gln Arg Arg Arg Asn Pro Gln Glu Gly Val Tyr Asn Ala Leu Gln 
    50                  55                  60                  


Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Thr Lys Gly Glu 
65                  70                  75                  80  


Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr 
                85                  90                  95      


Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Thr Leu Ala Pro 
            100                 105                 110         


Arg 
    


<210>  8
<211>  162
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Mouse Thy1.1

<400>  8

Met Asn Pro Ala Ile Ser Val Ala Leu Leu Leu Ser Val Leu Gln Val 
1               5                   10                  15      


Ser Arg Gly Gln Lys Val Thr Ser Leu Thr Ala Cys Leu Val Asn Gln 
            20                  25                  30          


Asn Leu Arg Leu Asp Cys Arg His Glu Asn Asn Thr Lys Asp Asn Ser 
        35                  40                  45              


Ile Gln His Glu Phe Ser Leu Thr Arg Glu Lys Arg Lys His Val Leu 
    50                  55                  60                  


Ser Gly Thr Leu Gly Ile Pro Glu His Thr Tyr Arg Ser Arg Val Thr 
65                  70                  75                  80  


Leu Ser Asn Gln Pro Tyr Ile Lys Val Leu Thr Leu Ala Asn Phe Thr 
                85                  90                  95      


Thr Lys Asp Glu Gly Asp Tyr Phe Cys Glu Leu Arg Val Ser Gly Ala 
            100                 105                 110         


Asn Pro Met Ser Ser Asn Lys Ser Ile Ser Val Tyr Arg Asp Lys Leu 
        115                 120                 125             


Val Lys Cys Gly Gly Ile Ser Leu Leu Val Gln Asn Thr Ser Trp Met 
    130                 135                 140                 


Leu Leu Leu Leu Leu Ser Leu Ser Leu Leu Gln Ala Leu Asp Phe Ile 
145                 150                 155                 160 


Ser Leu 
        


<210>  9
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-human CD19 variable heavy chain derived from the FMC63 anti-
       CD19 antibody

<400>  9

Glu Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr 
            20                  25                  30          


Gly Val Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys 
    50                  55                  60                  


Ser Arg Leu Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala 
                85                  90                  95      


Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Ser Val Thr Val Ser Ser 
        115                 120 


<210>  10
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-murine CD19 variable light chain derived from the FMC63 
       anti- CD19 antibody

<400>  10

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 
        35                  40                  45              


Tyr His Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 
            100                 105     


